BSE filing, NSE: THYROCARE. Summary written from the filing by ALFA Finder's alert engine.
Thyrocare Technologies Ltd: key numbers
- Share price
- ₹494.00
- Market cap
- ₹7,863 Cr
- Revenue (annual)
- ₹829.0 Cr
- Net profit (annual)
- ₹163.0 Cr
- P/E (TTM)
- 54.5×Sector 53.4×
- Promoter holding
- 51.02%-9.90% QoQ
- FII holding
- 9.37%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Thyrocare Technologies Ltd
All →Thyrocare Technologies Management Change
Thyrocare Technologies' Chief Scientific Officer, Dr. Preet Kaur, resigns effective November 6, 2026. The company is identifying a replacement and will disclose details later.
Thyrocare Technologies Other Announcement
Thyrocare disclosed NSE market purchases by an immediate relative and a KMP on 2 November 2026. Combined consideration is about Rs 0.11 Crore, with no promoter involved.
- Value
- ₹0.11 Cr
Thyrocare Technologies Merger & Restructuring Worth ₹141.4 Cr
Thyrocare agreed to sell its entire stake in subsidiary Nueclear Healthcare to Trovera. The consideration is about Rs 141.40 Crore, including preference shares and cash.
- Value
- ₹141.4 Cr
Thyrocare Technologies Annual General Meeting
Thyrocare Technologies reported postal ballot voting results approving the purchase of land and building from, and divestment of its entire shareholding in, Nueclear Healthcare Limited.
Thyrocare Technologies Earnings Call Transcript: Key Takeaways
Thyrocare reports robust 24% growth, pivoting from volume-led routine testing to specialized diagnostics under new management. High operational leverage is evident as PAT growth significantly outpaced revenue.
- Call
- Guides 20% growth
Thyrocare Technologies Investor Presentation: Key Takeaways
Q2 FY27 consolidated revenue ₹270.8 Cr (+25.1%), EBITDA ₹89.3 Cr (33.0% margin), PAT before exceptions ₹60.2 Cr (+25.7%). Debt-free; NHL radiology divestment pending.
Other employee stock options announcements
All →Piramal Finance Employee Stock Options
Piramal Finance allotted 6,00,000 equity shares to its ESOP Trust under the 2025 employee scheme. Paid-up share capital rises to Rs 47,44,60,612 across 23,72,30,306 shares.
Prime Fresh Employee Stock Options
Prime Fresh's Nomination and Remuneration Committee granted 86,850 stock options to eligible employees under its 2024 ESOP plan. The options vest after one year, with no exercise price or cash proceeds disclosed.
- Execution
- 01 year vesting from date of grant; exercisable within one year after vesting completion
HCP Plastene Bulkpack Employee Stock Options
HCP Plastene Bulkpack granted 140,100 ESOP options to eligible employees under its ESOP Scheme 2022. Each option converts into one ₹10 equity share on vesting and exercise.
NOCIL Employee Stock Options
NOCIL allotted 18,150 equity shares to senior management on exercising 2017 stock options at Rs 84.05 each. Paid-up capital rises to Rs 167.04 Crore.
Honasa Consumer Employee Stock Options
Honasa Consumer's board granted 1,61,700 stock options to eligible employees under its ESOP 2018 plan at Rs 10 exercise price. The grant is an employee stock option event with no cash proceeds recorded yet.
IDFC First Bank Employee Stock Options
IDFC FIRST Bank allotted 35,45,636 equity shares to employees on exercise of ESOS options, raising paid-up capital to ₹86,28,37,12,890. No cash consideration figure is disclosed in the filing.